|
|
Article: Pyrosequencing and Thomas Jefferson University to Develop Applications for Inflammatory Bowel Disease.
- Article from:
- PR Newswire
- Article date:
- March 31, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pyrosequencing AB (Stockholm: PYRO A) and Thomas Jefferson University, Philadelphia, announced today that they have entered into a sponsored research agreement to analyze genes and develop applications for inflammatory bowel disease (IBD). Thomas Jefferson University recently purchased a PSQ(TM)HS 96A System, Pyrosequencing's high sensitivity genotyping platform, to advance clinical molecular genetics research including IBD.
"This genotyping system developed by Pyrosequencing will allow us to develop a new gene-based diagnostic tool that we expect to be much simpler and faster, while as effective as current methods," said Paolo Fortina, M.D., Ph.D., professor of ...